ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
DAMORA THERAPEUT
28.10
+1.26
4.69%
盤後:
28.10
0.0000
0.00%
19:30 EDT
成交量:
52.54萬
成交額:
1,469.04萬
市值:
17.30億
市盈率:
-2.85
高:
28.53
開:
27.32
低:
26.87
收:
26.84
52周最高:
38.33
52周最低:
2.53
股本:
6,155.32萬
流通股本:
4,764.87萬
量比:
1.13
換手率:
1.10%
股息:
- -
股息率:
- -
每股收益(TTM):
-9.8764
每股收益(LYR):
-153.9532
淨資產收益率:
-99.74%
總資產收益率:
-21.61%
市淨率:
4.48
市盈率(LYR):
-0.18
資料載入中...
總覽
公司
新聞
公告
Damora Therapeutics啓動Dmr-001治療突變CALR驅動型原發性血小板增多症與骨髓纖維化的Clarity-101 1/1B期臨床試驗
美股速递
·
08/05
美國研究綜述-黑石集團、哈特福德保險公司、澤夫拉治療公司
路透中文
·
07/27
傑富瑞首次覆蓋Damora Therapeutics,給予買入評級,目標價50美元
美股速递
·
07/27
美國研究綜述-思科、DTE能源、美滿科技
路透中文
·
05/14
Galecto Inc旗下Damora計劃於2026年中提交DMR-001新藥臨床試驗申請 概念驗證數據預計2027年中公布
美股速递
·
03/09
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/DMRA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":28.1,"timestamp":1789156800000,"preClose":26.84,"halted":0,"volume":525410,"hourTrading":{"tag":"盘后","latestPrice":28.1,"preClose":28.1,"latestTime":"19:30 EDT","volume":10753,"amount":302160.02,"timestamp":1789169408731,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04694485842026831,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"休市中","change":1.26,"latestTime":"09-11 16:00:00 EDT","open":27.32,"high":28.53,"low":26.87,"amount":14690405.8049,"amplitude":0.061848,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":26.84,"postHourTrading":{"tag":"盘后","latestPrice":28.1,"preClose":28.1,"latestTime":"19:30 EDT","volume":10753,"amount":302160.02,"timestamp":1789169408731,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1304901638039173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":1.1304901638039173,"shares":61553200,"dividePrice":0,"high":28.53,"amplitude":0.061848,"preClose":26.84,"low":26.87,"week52Low":2.53,"pbRate":"4.48","week52High":38.3251,"institutionHeld":0,"latestPrice":28.1,"eps":-9.876431,"divideRate":0,"volume":525410,"delay":0,"ttmEps":-9.876431,"open":27.32,"prevYearClose":23.01,"prevWeekClose":30.06,"prevMonthClose":28.18,"prevQuarterClose":26.01,"fiveDayClose":28,"twentyDayClose":30.73,"sixtyDayClose":20.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785124800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-09-11","current":-2.845157,"percent":0.81746,"low":-100.260711,"twenty":-7.706597,"median":-7.187671,"eighty":-6.346489,"high":-5.207587,"avg":-12.339462,"sd":20.848416,"marketCap":1656981329},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580},{"date":"2026-08-28","current":-7.187671,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"marketCap":1889106881},{"date":"2026-09-04","current":-6.576954,"twenty":-7.707949,"median":-7.198831,"eighty":-6.380999,"marketCap":1728594532},{"date":"2026-09-11","current":-6.30448,"twenty":-7.706597,"median":-7.187671,"eighty":-6.346489,"marketCap":1656981329}],"updateTime":1789272816122},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1112635870","title":"Damora Therapeutics啓動Dmr-001治療突變CALR驅動型原發性血小板增多症與骨髓纖維化的Clarity-101 1/1B期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1112635870","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112635870?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 20:01","pubTimestamp":1785931269,"startTime":"0","endTime":"0","summary":"Damora Therapeutics正式启动一项名为Clarity-101的1/1B期临床试验,旨在评估其候选药物Dmr-001在突变型钙网蛋白驱动的原发性血小板增多症及骨髓纤维化患者中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654901371","title":"美國研究綜述-黑石集團、哈特福德保險公司、澤夫拉治療公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2654901371","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654901371?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 16:57","pubTimestamp":1785142662,"startTime":"0","endTime":"0","summary":"美国研究综述-黑石集团、哈特福德保险公司、泽夫拉治疗公司路透7月27日-周一,华尔街证券分析师下调了对包括黑石集团、哈特福德保险公司和泽夫拉治疗公司等数家在美国上市企业的评级和目标股价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBC","AAPL","AMAL","CYH","GM","AGIO","CATY","PRVT","BWXT","HIG","CPF","DMRA","FHB","BY","AAPY","BBRE","FRBA","XAR","FMBH","F","BAH","FTAI","FTNT","HON","HWM","ITA","AXP","FCNCA","IXN","CLF","DLR","AAPD","BANR","BAX","FVCB","UTES","CHTR","CEG","FISI","AAL","CELC","ARLO","BAM","CUBI","JRE","BX","SRCE","FLG","CDRE","CRED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105165649","title":"傑富瑞首次覆蓋Damora Therapeutics,給予買入評級,目標價50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105165649","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105165649?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 14:03","pubTimestamp":1785132188,"startTime":"0","endTime":"0","summary":"杰富瑞(Jefferies)近日对Damora Therapeutics(重组前)启动覆盖研究,给予其“买入”评级,并将目标股价设定为50美元。这一举措凸显了市场对该公司发展前景的乐观预期,分析师认为其具备显著的成长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635995937","title":"美國研究綜述-思科、DTE能源、美滿科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2635995937","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635995937?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 15:25","pubTimestamp":1778743532,"startTime":"0","endTime":"0","summary":"美国研究综述-思科、DTE能源、美满科技路透5月14日 - 周四,华尔街证券分析师调整了多家在美国上市公司的评级和目标股价,其中包括思科、DTE能源和美满科技。股票条目按字母顺序排列。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4S41R0NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STAA","KRMN","DMRA","LU1989764748.USD","MOH","USFD","CMS","LU1074936037.SGD","XEL","LU0661504455.SGD","TNGX","WY","GSHD","ARMK","NHI","DTE","DOCS","USPH","LU2023251221.USD","IE00BFTCPJ56.SGD","AMGN","ABBV","IE00BSNM7G36.USD","LU0868494708.USD","ARVN","MRVL","HLIO","AEE","CAKE","DT","LU1244550221.USD","LU1093756168.USD","CMP","LU0234570918.USD","LU0444971666.USD","MAIN","VSH","WEC","JACK","EYE","LU0054578231.USD","CSCL","MIRM","LU1084165304.USD","MRVU","MVLL","TXRH","BK4606","CSCO","CSCS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151744301","title":"Galecto Inc旗下Damora計劃於2026年中提交DMR-001新藥臨床試驗申請 概念驗證數據預計2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1151744301","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151744301?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:07","pubTimestamp":1773058034,"startTime":"0","endTime":"0","summary":"生物技术公司Galecto Inc.近日披露其子公司Damora的最新研发进展。根据规划,Damora拟于2026年中期向监管机构提交DMR-001的新药临床试验申请或临床试验授权,该时间表标志着其在纤维化疾病治疗领域的重要里程碑。与此同时,针对DMR-001的概念验证关键数据集预计将在2027年中期揭晓。此次进展凸显了Galecto Inc.通过Damora平台深化其在创新疗法领域的战略布局。若后续研究顺利推进,DMR-001有望为特定纤维化疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","GLTO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}